HER-2 Positive Breast Cancer Terminated Phase 1 Trials for Doxorubicin (DB00997)

IndicationStatusPhase
DBCOND0042425 (HER-2 Positive Breast Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02131506A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast CancerTreatment